Novavax (NVAX) Set to Announce Quarterly Earnings on Friday

Novavax (NASDAQ:NVAX) is scheduled to announce its earnings results before the market opens on Friday, May 10th. Analysts expect the company to announce earnings of ($1.04) per share for the quarter. Novavax has set its Q1 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors that are interested in registering for the company’s conference call can do so using this link.

Novavax (NASDAQ:NVAX) last announced its quarterly earnings data on Wednesday, February 28th. The biopharmaceutical company reported ($1.44) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.95). The firm had revenue of $291.34 million during the quarter, compared to the consensus estimate of $310.96 million. The company’s quarterly revenue was down 18.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($2.28) earnings per share. On average, analysts expect Novavax to post $-1 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Novavax Price Performance

Shares of NVAX stock opened at $4.47 on Thursday. The stock’s fifty day simple moving average is $4.67 and its 200 day simple moving average is $4.99. The firm has a market cap of $627.60 million, a price-to-earnings ratio of -0.81 and a beta of 1.63. Novavax has a one year low of $3.53 and a one year high of $11.36.

Analyst Upgrades and Downgrades

Separately, HC Wainwright decreased their price target on Novavax from $35.00 to $19.00 and set a “buy” rating on the stock in a research note on Friday, March 1st.

About Novavax

Novavax, Inc, a biotechnology company, that promotes improved health by discovering, developing, and commercializing vaccines to protect against serious infectious diseases. It offers vaccine platform that combines a recombinant protein approach, nanoparticle technology, and its patented Matrix-M adjuvant to enhance the immune response.